PatentAug 6, 2026, 09:17 AM
Creative Medical gets US patent allowance for MyeloCelz™ diabetes tech
AI Summary
Creative Medical Technology Holdings, Inc. announced it has received a Notice of Allowance from the USPTO for a patent application covering the use of exosomes from stem cell programmed myeloid cells to suppress Type 1 diabetes. This patent strengthens the intellectual property protection for its MyeloCelz™ platform, a cell-free exosome technology, and complements its existing diabetes pipeline, including clinical-stage programs CELZ-201 and CELZ-101. The company's total IP estate now includes approximately 60 patents and applications, positioning it to address the estimated $18 billion global Type 1 diabetes market.
Key Highlights
- Received a Notice of Allowance from USPTO for a patent application titled "Suppression of Diabetes Using Exosomes From Stem Cell Programmed Myeloid Cells".
- The patent will extend intellectual property protection for the proprietary MyeloCelz™ platform.
- The allowed claims cover the use of exosomes alone or in combination with other tolerance-promoting agents for Type 1 diabetes.
- This new patent complements the company's broader diabetes portfolio, including CELZ-201 and CELZ-101.
- Creative Medical's overall intellectual property estate now comprises approximately 60 issued patents and pending applications.
- The global Type 1 diabetes market is estimated at roughly $18 billion in 2026.
- Company plans to complete formal patent issuance, advance clinical programs, and evaluate strategic pathways.
Price Impact
More from CELZ